Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Goserelin acetate 3.6 mg Injection|DRUG: ZOLADEX® 3.6mg Injection
Sponsor: Eurofarma Laboratorios S.A.